China SXT Pharmaceuticals, Inc. Class A Ordinary Shares
Here’s whether China SXT Pharmaceuticals, Inc. Class A Ordinary Shares (SXTC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 43 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-18.66% over 10 days); weak 1-year return of -100.0%; 3-month momentum negative (-96.9%); rising volume on a downtrend (distribution, 1.62x avg). Currently 100.0% off its 52-week high. Score: -5/7.
SXTC is trading below its 200-day MA ($4,147.48) — a key warning sign the longer-term trend is under pressure. An RSI of 43.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -100.0% compares to +20.5% for SPY (trailed the market by 120.5%). The current 100.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.